ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2027 • ACR Convergence 2022

    Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome

    Uzma Nakshbandi1, Martha S. van Ginkel1, Silvia Liefers2, Hendrika Bootsma2, Fred Spijkervet2, Arjan Vissink1, Bert van der Vegt1 and Frans Kroese2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
  • Abstract Number: 2029 • ACR Convergence 2022

    Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity

    Liselotte Deroo1, Helena Achten2, Kristel De Boeck2, Eva Genbrugge2, Wouter Bauters2, Dimitri Roels2, Frederick Dochy2, David Creytens2, Filip Van den bosch3, Dirk Elewaut4 and isabelle peene5, 1Ghent University, Gent, Belgium, 2Ghent University Hospital, Gent, Belgium, 3Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 4Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, 5Ghent University Hospital, Ghent, Belgium

    Background/Purpose: Presence of anti-SSA/Ro antibodies is one of the 2016 ACR-EULAR classification criteria for primary Sjögren's Syndrome (pSS). Anti-SSA/Ro antibodies comprise reactivity against Ro52 and/or…
  • Abstract Number: 2018 • ACR Convergence 2022

    Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome

    Liseth de Wolff1, Suzanne Arends2, Alja Stel3, Greetje van Zuiden3, Jolien van Nimwegen2, Arjan Vissink4, Frans Kroese2, Gwenny Verstappen2 and Hendrika Bootsma2, 1UMCG, Zwolle, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 4University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
  • Abstract Number: 2024 • ACR Convergence 2022

    Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach

    Silvia Fonzetti1, Francesco Ferro2, Gaetano La Rocca3, Giovanni Fulvio4, Inmaculada Concepción Navarro García5, Gianmaria Governato6, Valentina Donati7, Marta Mosca8 and Chiara Baldini4, 1Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, 4University of Pisa, Pisa, Pisa, Italy, 5Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 6Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, 7Pathology Unit, University of Pisa, Pisa, Italy, 8Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
  • Abstract Number: 2028 • ACR Convergence 2022

    The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
  • Abstract Number: 2030 • ACR Convergence 2022

    Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome

    Jonathan Hubbard1, Kim Campbell1, Kathy Sivils1, Robert Hoffman1, Kim Hung Lo1, Jocelyn Leu1, Sophia Liva1, Qing Zuraw1, Anne Stevens1, Leona Ling2, Keith Karcher3, Sindhu Ramchandren3, Hong Sun3, Hal Scofield4, Daniel Wallace5 and Raphaèle Seror6, 1Janssen Research and Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Cambridge, MA, 3Janssen Research & Development, LLC, Titusville, NJ, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
  • Abstract Number: 1992 • ACR Convergence 2022

    Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry

    Joshua Baker1, J Morel Symons2, Jud C Janak3, Page Moore3, Elizabeth Kohl3, Bernice Gershenson3, Oksana Pugach3, Dave Webb4, Alan A Martin4, Didier Saurigny5 and Marguerite Bracher5, 1University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 2GlaxoSmithKline, Collegeville, PA, 3CorEvitas, LLC, Waltham, MA, 4GlaxoSmithKline, Brentford, United Kingdom, 5GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
  • Abstract Number: 1991 • ACR Convergence 2022

    Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation

    Siba Raychaudhuri1, Smriti Raychaudhuri2 and Heike Wulff3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, 2VA Medical Center, Sacramento, CA, 3UC Davis, Davis, CA

    Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1.…
  • Abstract Number: 2016 • ACR Convergence 2022

    Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Abelina Schneider3, Anne Pankow3, Linda Hartman4, Jose Pereira da Silva5, John Kirwan6, Siegfried Wassenberg7, Christian Dejaco8, Robin Christensen9, Maarten Boers10 and Frank Buttgereit11, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 5University of Coimbra, Rheumatology, Columbia, Portugal, 6University of Bristol, Bristol, United Kingdom, 7Rheumazentrum Ratingen, Ratingen, Germany, 8Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
  • Abstract Number: 1990 • ACR Convergence 2022

    Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments

    Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA

    Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
  • Abstract Number: 1490 • ACR Convergence 2022

    High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis

    Nuria Barbarroja1, Laura Cuesta-Lopez1, Carlos Pérez-Sánchez1, Ariana Barberá-Betancourt2, Ivan Arias-de la Rosa1, Miriam Ruiz-Ponce1, Clementina Lopez-Medina3, Ignacio Gómez-Garcia4, lourdes Ladehesa-Pineda5, Maria del Carmen Abalos-Aguilera6, Chary López-Pedrera7, Alejandro Escudero-Contreras1 and Eduardo Collantes1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2University of Cambridge, Cambridge, United Kingdom, 3Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, 4IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 5Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 6Hospital Universitario Reina Sofia, Cordoba, Spain, 7Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain

    Background/Purpose: A significant progress has recently been made in the identification of molecular profiles involved in the pathogenesis of chronic autoinflammatory diseases through the use…
  • Abstract Number: 1491 • ACR Convergence 2022

    Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance

    David Kiefer1, Juergen Braun1, Lucia Schneider1, Niklas Kolle1, Uta Kiltz1, Ioana Andreica2, Philipp Sewerin1, Bjoern Buehring3, susanne herbold1 and Xenofon Baraliakos4, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Bergisches Rheuma-Zentrum, Velbert, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
  • Abstract Number: 1986 • ACR Convergence 2022

    Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment

    Sofie Falkenløve Madsen1, Dovile Sinkeviciute2, Christian Thudium2, Morten Karsdal2 and Anne-Christine Bay-Jensen2, 1University of Copenhagen / Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
  • Abstract Number: 2023 • ACR Convergence 2022

    Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms

    Martha Tsaliki1, Joshua Cavett1, Biji T. Kurien2, Christina Bruxvoort1, Robert Hal Scofield2 and Kristi A Koelsch3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Sjögren’s Syndrome (SS) diagnosis depends on clinic examinations that involve measurements of serum levels of anti-Ro\SSA, anti-La\SSB, and rheumatoid factor antibodies; the first is…
  • Abstract Number: 1493 • ACR Convergence 2022

    Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry

    Philip J Mease1, Miroslawa Nowak2, Jiyoon Choi3, Tom Lehman2, Antoine Sreih4, Taylor Blachley5, Blessing Dube5, Kaylee Ho5, Nicole Middaugh5 and Alexis Ogdie6, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Bristol Myers Squibb, Princeton, NJ, 3Bristol Myers Squibb, Lawrenceville, NJ, 4Bristol Myers Squibb, Philadelphia, PA, 5CorEvitas, LLC, Waltham, MA, 6Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…
  • « Previous Page
  • 1
  • …
  • 452
  • 453
  • 454
  • 455
  • 456
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology